Ask AI
ProCE Banner Activity

NeoADAURA: Neoadjuvant Osimertinib ± CT vs CT Alone in Resectable EGFRm NSCLC

Conference Coverage
Slideset

In the phase III NeoADAURA study, preoperative treatment with osimertinib ± CT vs CT + placebo resulted in a statistically significant improvement in the MPR rates vs CT alone in patients with resectable stage II-IIIB EGFRm NSCLC, with more patients being down-staged prior to surgery and fewer patients being precluded from definitive surgery.

Released: June 06, 2025

Expiration: December 05, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar